Evaluating the potential of candidate surrogate endpoints for overall survival in treatment-naive metastatic melanoma treated with anti-PD-1-based regimens with or without anti-CTLA-4 therapy
- DOI
- 10.1136/jitc-2026-016440
- Published
- 2026-09
- Container
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1136/jitc-2026-016440,
title = {Evaluating the potential of candidate surrogate endpoints for overall survival in treatment-naive metastatic melanoma treated with anti-PD-1-based regimens with or without anti-CTLA-4 therapy},
author = {Pierre Squifflet and Everardo D Saad and Murat Kurt and James Larkin and Peter Mohr and Andriy Moshyk and Marc Buyse},
year = {2026},
journal = {Journal for ImmunoTherapy of Cancer},
doi = {10.1136/jitc-2026-016440},
url = {https://doi.org/10.1136/jitc-2026-016440}
}RIS
TY - JOUR TI - Evaluating the potential of candidate surrogate endpoints for overall survival in treatment-naive metastatic melanoma treated with anti-PD-1-based regimens with or without anti-CTLA-4 therapy AU - Pierre Squifflet AU - Everardo D Saad AU - Murat Kurt AU - James Larkin AU - Peter Mohr AU - Andriy Moshyk AU - Marc Buyse PY - 2026 JO - Journal for ImmunoTherapy of Cancer DO - 10.1136/jitc-2026-016440 UR - https://doi.org/10.1136/jitc-2026-016440 ER -
APA
Squifflet, P., Saad, E. D., Kurt, M., Larkin, J., Mohr, P., Moshyk, A., & Buyse, M. (2026). Evaluating the potential of candidate surrogate endpoints for overall survival in treatment-naive metastatic melanoma treated with anti-PD-1-based regimens with or without anti-CTLA-4 therapy. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2026-016440
Source records
- crossref · retrieved 2026-09-27T06:59:30.065Z